I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $339.22M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
| | ||||
4SC AG |
Martinsried, Germany |
5/21 |
€9 (US$10.4) |
4SC raised US$10.4M in a third round of financing; investors were 3i Group, Deutsche Venture Capital DVC, Mulligan Biocapital, Beteiligungs-gesellschaft fur die Deutsche Wirtschaft and BioM |
|
||||
Acorda |
Hawthorne, N.Y. |
5/9 |
$55.3 |
Acorda raised $55.3M in a private financing led by Easton Hunt Capital Partners; other investors were ABN AMRO Capital, Cross Atlantic Partners, JP Morgan Fleming Asset Management and Techno Venture Management |
|
||||
Ambion Inc. |
Austin, Texas |
5/2 |
$10.5 |
Ambion raised $10.5M in a financing led by Telegraph Hill Parnters LP |
|
||||
AusAm Biotechnologies |
Santa Monica, Calif. |
5/13 |
$5.5 |
AusAm raised $5.5M after closing a Series B round of financing |
|
||||
BioAlliance |
Paris |
5/19 |
€10 |
BioAlliance completed a US$11.66M third round of financing led by Auriga Partners; other investors were ING, the French Co-Investment Fund, Capricorn Venture Partners, ABN-AMRO Capital France, SPEF Ventures and a number of individuals |
|
||||
BioMimetic Pharmaceuticals |
Nashville, Tenn. |
5/28 |
ND |
BioMimetic received venture capital funding through lead investor Memphis Biomed Ventures and existing investors Burrill and Co., Holden Capital and Novo A/S |
|
||||
BioXell SpA |
Milan, Italy |
5/21 |
€17 |
BioXell raised US$19.9M in a second round of financing led by NIB Capital Private Equity; other investors were MPM Capital, Index Ventures, Life Sciences Partners and Piccole Imprese |
|
||||
Cellerant |
Palo Alto, Calif. |
5/29 |
$10 |
Cellerant raised $10M in its first round; investors were Allen & Co. LLC, MPM Capital and company founders (5/29) |
|
||||
CellFactors plc |
Newport, UK |
5/14** |
£0.37 |
CellFactors raised a total of US$4M in a private round that began in April; US$3.3M of the financing was accounted for in the April chart |
|
||||
Compound Therapeutics Inc. |
Waltham, Mass. |
5/28 |
$12 |
Compound raised $12M in a Series A round co-led by Atlas Venture, Flagship Ventures and Polaris Venture Partners |
|
||||
Diatos SA |
Paris |
5/7 |
€2.5 |
Diatos raised US$2.96M from NIF Ventures, bringing the total for the round announced in February to US$10.66M |
|
|
|||
Galileo Pharmaceuticals Inc. |
Santa Clara, Calif. |
5/1 |
$31 |
Galileo raised $31M in a preferred stock offering; investors were Alloy Ventures, Adams Street Partners, Bay City Capital, Bay City's North American Nutrition and Agribusiness Fund, Johnson & Johnson Development Corp., Inventages Venture Capital, Novartis BioVenture Fund and the Biomedical Sciences Investment Fund of the Singapore Economic Development Board |
|
||||
GlycoMimetics Inc. |
Rockville, Md. |
5/22 |
$4.3 |
GlycoMimetics raised $4.3M in a Series A financing round led by New Enterprise Associates; other investors were Alliance Technology Ventures, Anthem Capital and the Novartis Venture Fund |
|
|
|||
Innodia Inc. |
Montreal |
5/8 |
C$7 (US$5) |
Innodia raised US$5M in a Series A round led by Picchio Pharma Inc. and participated in by Biomedicine LP |
|
||||
Momenta Pharmaceuticals |
Cambridge, Mass. |
5/22 |
$19 |
Momenta raised $19M in a second round led by MVM Life Science Partners and Atlas Venture; other investors were Cardinal Partners and Polaris |
|
||||
Novocell Inc. |
Irvine, Calif. |
5/2 |
$4.3 |
Novocell closed its Series D round for $4.3M; investors were Asset Management, Alloy Ventures, BD Ventures LLC, SurModics Inc. and The Vertical Group |
|
||||
Rib-X Pharmaceuticals |
New Haven, Conn. |
5/1 |
$51 |
Rib-X raised $51M in a Series B placement of preferred stock; investors were Axiom Venture Partners, Cardinal Partners, Connecticut Innovations, EuclidSR Partners, Oxford Bioscience Partners, S.R. One Ltd. and Zero Stage Capital |
|
||||
Santarus |
San Diego |
5/22 |
$51.4 |
Santarus raised $51.4M in a third round led by S.R. One Ltd.; other investors were Life Sciences Partners, Hamilton Apex Technology Ventures, China Development Industrial Bank, New England Partners, St. Paul Venture Capital, Advent Partners, Domain Associates LLC, JPMorgan Partners, Windamere Capital Ventures and Fog City Fund; Rockport Venture Partners assisted the company with the private placement |
|
||||
Sidec |
Stockholm, Sweden |
5/28** |
SEK10 |
Sidec raised US$1.3M in a second funding round |
|
||||
Symyx Therapeutics Inc. (spin-off of Symyx Technologies Inc.; SMMX) |
Santa Clara, Calif. |
5/9 |
$8 |
Symyx Therapeutics raised $8M in a Series A round led by The Sprout Group; 5am Ventures also participated |
|
||||
U.S. Genomics |
Woburn, Mass. |
5/7 |
$25 |
U.S. Genomics raised $25M in a private financing round |
|
||||
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $23M | ||||
Company |
Partner (Country) |
Amt. (M) |
Triggering Event |
Details (Date) |
|
| ||||
Abgenix Inc. (ABGX) |
Human Genome Sciences Inc. (HGSI) |
ND |
Milestone payment |
Abgenix earned the payment after Human Genome Sciences licensed rights to develop a fully human monoclonal antibody to the CCR5 receptor (5/12) |
|
||||
ImClone |
Merck KgaA (Germany) |
$6 |
Milestone payment |
ImClone received the payment following Merck's approval of an import license from German regulatory authorities in connection with the Erbitux license agreement (5/27) |
|
||||
Isotechnika Inc. (Canada; TSE:ISA) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
C$21.9 (US$16) |
Milestone payment |
Isotechnika received a US$16M milestone payment for positive findings from a Phase II psoriasis trial of ISA247 (5/16) |
|
||||
Karo Bio AB (Sweden; SSE:KARO) |
Merck & Co. Inc. |
ND |
Milestone payment |
Karo Bio received the payment as part of a collaboration to develop new treatments in the field of estrogen receptors (5/8) |
|
||||
Renovis Inc.* |
AstraZeneca plc (UK) |
ND |
Milestone payment |
Renovis received the payments for the advancement of Cerovive into two Phase III trials for acute ischemic stroke (5/27) |
|
||||
Transform Pharmaceuticals Inc.* |
Eli Lilly & Co. |
$1 |
Milestone payment |
Transform received the payment for attaining several success factors in the collaboration to enhance the process by which Lilly selects and optimizes early lead candidates (5/7) |
|
||||
| | ||||
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Denotes privately held company. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.